By Fineline Cube Thermo Fisher Scientific Inc. (NYSE: TMO), the global life sciences leader, announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to accelerate the PRECISE-SG100K population health initiative—a large-scale effort to integrate deep proteomic profiling into precision medicine. The partnership will deploy Thermo Fisher’s integrated proteomics ecosystem, combining the Olink Proximity Extension Assay (PEA) platform, the Orbitrap Astral™ high-resolution mass spectrometry system, and Seer’s Proteograph™ Product Suite to generate real-time biological insights for early disease detection and personalized intervention.
Technology Integration Framework
| Component | Role in PRECISE-SG100K |
|---|---|
| Olink PEA Platform | High-sensitivity, targeted quantification of 3,000+ proteins from minimal sample volumes |
| Orbitrap Astral MS | Ultra-fast, high-resolution discovery proteomics with deep coverage (>10,000 proteins/sample) |
| Seer Proteograph | Nanoparticle-based sample prep enabling unbiased, scalable plasma proteome analysis |
| Data Synthesis | Unified workflow linking targeted validation with hypothesis-free discovery |
This multi-modal approach allows researchers to simultaneously conduct deep exploratory proteomics and high-throughput clinical-grade protein monitoring—a critical capability for identifying early biomarkers of chronic and infectious diseases in diverse Asian populations.
Strategic Objectives of PRECISE-SG100K
- Enroll 100,000+ Singaporean participants across ethnic groups (Chinese, Malay, Indian)
- Establish a longitudinal proteogenomic biobank linked to electronic health records
- Identify proteomic signatures predictive of diabetes, cardiovascular disease, cancer, and neurodegenerative conditions
- Enable precision prevention strategies through dynamic risk stratification
Thermo Fisher’s end-to-end proteomics infrastructure provides the scalability and analytical rigor required for population-level studies, positioning the PRECISE-SG100K as one of Asia’s most ambitious precision health programs.
Market & Scientific Implications
- Proteomics Momentum: Reflects growing institutional adoption of proteomics as a complement to genomics in precision medicine
- Commercial Validation: Strengthens Thermo Fisher’s leadership in integrated multi-omics solutions amid rising demand from national biobanks
- Asian Health Equity: Addresses historical underrepresentation of Asian populations in global proteomic datasets
- Platform Synergy: Demonstrates seamless interoperability between Thermo Fisher’s acquired assets (Olink, Seer) and core MS technology
Forward-Looking Statements
This brief contains forward-looking statements regarding collaboration scope, technological performance, and research outcomes. Actual results may vary due to study execution, data interpretation, and regulatory or operational factors.-Fineline Info & Tech